- Home
- OGS vs LEGN Comparison
OGS vs LEGN Comparison
Compare OGS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OGS | LEGN |
|---|---|---|
| Founded | 1906 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OGS | LEGN |
|---|---|---|
| Price | $87.55 | $23.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $89.00 | $61.33 |
| AVG Volume (30 Days) | 380.9K | ★ 2.3M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $2,578,005,000.00 | N/A |
| Revenue This Year | $12.51 | $42.68 |
| Revenue Next Year | N/A | $30.52 |
| P/E Ratio | $20.13 | ★ N/A |
| Revenue Growth | ★ 42.54 | N/A |
| 52 Week Low | $70.87 | $16.24 |
| 52 Week High | $90.78 | $45.30 |
Technical Indicators
Market Signals| Indicator | OGS | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 66.20 |
| Support Level | $84.18 | $20.70 |
| Resistance Level | $87.96 | $26.72 |
| Average True Range (ATR) | 1.74 | 1.37 |
| MACD | -0.26 | 0.50 |
| Stochastic Oscillator | 35.14 | 68.61 |
Price Performance
Historical ComparisonAbout OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. It operates in one reportable business segment: regulated public utilities that deliver natural gas to residential, commercial, and transportation customers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.